PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
•Market ecosystem
•Market characteristics
•Market segmentation analysis

PART 05: MARKET SIZING
•Market definition
•Market sizing 2017
•Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS
•Bargaining power of buyers
•Bargaining power of suppliers
•Threat of new entrants
•Threat of substitutes
•Threat of rivalry
•Market condition

PART 07: MARKET SEGMENTATION BY APPLICATION
•Segmentation by application
•Comparison by application
•Genetic diseases
•Non-genetic diseases
•Market opportunity by application

PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE
•Geographical segmentation
•Regional comparison
•Americas
•EMEA
•APAC
•Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
•Market drivers
•Market challenges

PART 12: MARKET TRENDS
•Increasing number of research activities on human genomics
•Growing technological improvements in DNA sequencing
•Increasing M&A

PART 13: VENDOR LANDSCAPE
•Overview
•Landscape disruption

PART 14: VENDOR ANALYSIS
•Vendors covered
•Vendor classification
•Market positioning of vendors
•Agilent Technologies
•BGI
•F. Hoffmann-La Roche
•Illumina
•Laboratory Corporation of America
•Natera
•Other prominent vendors

PART 15: APPENDIX
•List of abbreviations

List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global DNA sequencing market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global prenatal DNA sequencing market 2017-2022 ($ mn)
Exhibit 09: Global prenatal DNA sequencing market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Market condition - Five forces 2022
Exhibit 19: Global prenatal DNA sequencing market by application – Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Common types of genetic disorders
Exhibit 22: Global prenatal DNA sequencing market by genetic diseases – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global prenatal DNA sequencing market by genetic diseases – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global prenatal DNA sequencing market by non-genetic diseases – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global prenatal DNA sequencing market by non-genetic diseases – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: R&D funding for cancer 2013-2016 ($ millions)
Exhibit 41: Cost of sequencing per genome 2001-2015 ($)
Exhibit 42: Prominent M&A in DNA sequencing market 2007-2014
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Agilent Technologies overview
Exhibit 49: Agilent Technologies – Business segments
Exhibit 50: Agilent Technologies – Organizational developments
Exhibit 51: Agilent Technologies – Geographic focus
Exhibit 52: Agilent Technologies – Segment focus
Exhibit 53: Agilent Technologies – Key offerings
Exhibit 54: BGI: Overview
Exhibit 55: BGI: Business segments
Exhibit 56: BGI: Organizational developments
Exhibit 57: BGI: Geographic focus
Exhibit 58: BGI: Segment focus
Exhibit 59: BGI: Key offerings
Exhibit 60: F. Hoffmann-La Roche: Overview
Exhibit 61: F. Hoffmann-La Roche: Business segments
Exhibit 62: F. Hoffmann-La Roche: Organizational developments
Exhibit 63: F. Hoffmann-La Roche: Geographic focus
Exhibit 64: F. Hoffmann-La Roche: Segment focus
Exhibit 65: F. Hoffmann-La Roche: Key offerings
Exhibit 66: Illumina: Overview
Exhibit 67: Illumina: Business segments
Exhibit 68: Illumina: Organizational developments
Exhibit 69: Illumina: Geographic focus
Exhibit 70: Illumina: Segment focus
Exhibit 71: Illumina: Key offerings
Exhibit 72: Laboratory Corporation of America overview
Exhibit 73: Laboratory Corporation of America – Business segments
Exhibit 74: Laboratory Corporation of America– Organizational developments
Exhibit 75: Laboratory Corporation of America – Geographic focus
Exhibit 76: Laboratory Corporation of America – Segment focus
Exhibit 77: Laboratory Corporation of America– Key offerings
Exhibit 78: Natera overview
Exhibit 79: Natera – Business segments
Exhibit 80: Natera– Organizational developments
Exhibit 81: Natera – Geographic focus
Exhibit 82: Natera – Segment focus
Exhibit 83: Natera – Key offerings

Companies Mentioned
• Agilent Technologies
• BGI
• F. Hoffmann-La Roche
• Illumina
• Laboratory Corporation of America
• Natera
Other prominent vendors